Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: A phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma

被引：13
|
作者：
Venook, Alan P.
Blanke, Charles D.
Niedzwiecki, Donna
Lenz, Heinz-Josef
Taylor, John R.
Hollis, Donna R.
Sutherland, Susan
Goldberg, Richard M.
机构：
[1] Univ Calif San Francisco, Dept Clin Med, San Francisco, CA 94115 USA
[2] Canc & Leukemia Grp B, Chicago, IL USA
[3] SW Oncol Grp, San Antonio, TX USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Duke Univ, Durham, NC USA
[6] Univ So Calif, Los Angeles, CA USA
[7] Univ N Carolina, Chapel Hill, NC USA
来源：
CLINICAL COLORECTAL CANCER | 2007年 / 6卷 / 07期
关键词：
bevacizumab; cetuximab; FOLFIRI; FOLFOX;
D O I：
10.3816/CCC.2007.n.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：536 / 538
页数：3
相关论文
共 50 条
  • [1] Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
    Venook, Alan P.
    Blanke, Charles D.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Taylor, John R.
    Hollis, Donna R.
    Sutherland, Susan
    Goldberg, Richard A.
    CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 292 - 294
  • [2] Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial
    Van Blarigan, Erin L.
    Zhang, Sui
    Ou, Fang-Shu
    Venlo, Alan
    Ng, Kimmie
    Atreya, Chloe
    Van Loon, Katherine
    Niedzwiecki, Donna
    Giovannucci, Edward
    Wolfe, Eric G.
    Lenz, Heinz-Josef
    Innocenti, Federico
    O'Neil, Bert H.
    Shaw, James E.
    Polite, Blase N.
    Hochster, Howard S.
    Atkins, James N.
    Goldberg, Richard M.
    Mayer, Robert J.
    Blanke, Charles D.
    O'Reilly, Eileen M.
    Fuchs, Charles S.
    Meyerhardt, Jeffrey A.
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [3] PHASE-II TRIAL OF MITOXANTRONE IN PREVIOUSLY UNTREATED PATIENTS WITH COLORECTAL ADENOCARCINOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY
    COWAN, JD
    VONHOFF, DD
    MCDONALD, B
    TALLEY, RW
    MCCRACKEN, JD
    CHEN, T
    CANCER TREATMENT REPORTS, 1982, 66 (09): : 1779 - 1780
  • [4] Phase II evaluation of topotecan in patients with advanced colorectal cancer - A Southwest Oncology Group Trial (SWOG 9241)
    Macdonald, JS
    Benedetti, JK
    Modiano, M
    Alberts, DS
    INVESTIGATIONAL NEW DRUGS, 1997, 15 (04) : 357 - 359
  • [5] Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)
    John S. Macdonald
    Jacqueline K. Benedetti
    Manuel Modiano
    David S. Alberts
    Investigational New Drugs, 1997, 15 : 357 - 359
  • [6] PHASE-II TRIAL OF AMONAFIDE IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST-ONCOLOGY-GROUP-STUDY
    BROWN, TD
    GOODMAN, PJ
    FLEMING, T
    MACDONALD, JS
    CRAIG, JB
    EINSTEIN, AB
    ANTI-CANCER DRUGS, 1993, 4 (01) : 49 - 50
  • [7] PHASE-II TRIAL OF ECHINOMYCIN IN ADVANCED COLORECTAL-CANCER - A SOUTHWEST ONCOLOGY GROUP-STUDY
    BROWN, TD
    GOODMAN, PJ
    FLEMING, TR
    TAYLOR, SA
    MACDONALD, JS
    INVESTIGATIONAL NEW DRUGS, 1991, 9 (01) : 113 - 114
  • [8] Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study
    Robert P. Whitehead
    Sheryl McCoy
    John S. Macdonald
    Saul E. Rivkin
    Marcus A. Neubauer
    Shaker R. Dakhil
    Heinz-Josef Lenz
    Michael S. Tanaka
    James L. Abbruzzese
    Investigational New Drugs, 2006, 24 : 335 - 341
  • [9] Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study
    Whitehead, RP
    McCoy, S
    Macdonald, JS
    Rivkin, SE
    Neubauer, MA
    Dakhil, SR
    Lenz, HJ
    Tanaka, MS
    Abbruzzese, JL
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (04) : 335 - 341
  • [10] Phase II trial of trimetrexate in advanced esophageal cancer: A Southwest Oncology Group Study
    Fleming, TR
    Brown, TD
    Ross, SW
    Macdonald, JS
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (04) : 363 - 365
12345